21st Century Medicine (21CM) is a California cryobiological research company which has as its primary focus the development of perfusates and protocols for viable long-term cryopreservation of human organs, tissues and cells at cryogenic temperatures (temperatures below −100 °C) through the use of vitrification. 21CM was founded in 1993.
Dr. Gregory M. Fahy, who pioneered the use of vitrification in reproductive cryopreservation, serves on the company’s Board of Directors and prioritizes, develops and directs the company’s research activities. He also manages all extramural collaborative research projects with universities, industry and research institutions to create specific products and services.
The company holds a number of patents, most notably for cryoprotectant mixtures that greatly reduce ice formation while minimizing cryoprotectant toxicity, as well as for synthetic ice-blockers that inexpensively simulate the antifreeze protein found in arctic organisms. Their website lists peer-reviewed journal publications based on research conducted in their laboratories. In 2004 21CM received a $900,000 grant from the U.S. National Institutes of Health (NIH) to study a preservation solution developed by the University of Rochester in New York for extending simple cold storage time of human hearts removed for transplant.